Roche says lung cancer drug Alecensa shows promise in Phase 3 trial


By David Sachs

Roche said Friday that its Alecensa drug demonstrated the ability to reduce recurrence of lung cancer for patients in the early stage of the disease.

The Swiss pharmaceutical company said the results, from a Phase 3 study of 257 people which compared the treatment with platinum-based chemotherapy, met its primary goal of disease-free survival in people with early-stage non-small cell lung cancer. About half of people with this type of lung cancer experience a recurrence of the disease after surgery, Roche said.

Roche said that it found no unexpected safety issues and will submit the data to global health authorities.

Write to David Sachs at

This article was originally published by Read the original article here.

Previous article: Apple’s stock heads for longest winning streak in more than a year
Next article: ‘The next frontier’ in growing diversity backlash: programs to help Black businesses and entrepreneurs


Please enter your comment!
Please enter your name here